IRIX — IRIDEX Corporation

IRIDEX Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $11.8 million, flat year-over-year compared to $11.9 million in Q1 2025, aligning with guidance.
• Gross Profit: $4.7 million, representing a 40% gross margin, down from 43% in the prior year due to increased manufacturing costs.
• Operating Expenses: $5.1 million, a decrease of 4% year-over-year, attributed to reduced general and administrative costs.
• Net Loss: $500,000 or $0.03 per share, improved from a net loss of $1.7 million or $0.10 per share in Q1 2025.
• Adjusted EBITDA: $300,000, down from $400,000 in the prior year.
• Cash Position: $4.6 million, a decrease of $1.4 million during the quarter, with expectations of positive cash flow for the remainder of 2026.

2. Strategic Updates and Business Highlights

• Glaucoma Business: Strong performance with G-Probes sales increasing to 15,500 units from 13,900 units year-over-year, driven by effective targeting strategies and increased average selling prices (ASP).
• Retina Portfolio: Focus on upgrading the PASCAL system and expanding international adoption. A partnership with iPro GPO aims to enhance market access for retina products.
• Cost Reduction Initiatives: Continued reduction in operating expenses and relocation of administrative functions out of California is expected to save approximately $600,000 annually.
• Manufacturing Transition: Ongoing shift to lower-cost third-party contract manufacturers, with full implementation expected by 2027, aimed at improving gross margins.

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Reaffirmed at $51 million to $53 million, excluding revenue from the Middle East, representing a pro forma growth of 1% to 5% compared to 2025.
• Seasonality: Q1 typically represents about 22% of annual revenue, with expectations for stronger performance in Q2 and Q4.
• Cash Flow: Anticipated positive cash flow for the full year, with sequential improvements expected as inventory is sold and receivables collected.

4. Bad News, Challenges, or Points of Concern

• Retina Sales Decline: Revenue from the retina segment decreased significantly due to international regulatory delays and supply chain issues, particularly affecting Japan and EndoProbes.
• Geopolitical Risks: Ongoing conflict in the Middle East has created market disruptions, impacting revenue potential in that region.
• Gross Margin Pressure: Despite sequential improvement, gross margins remain under pressure from rising manufacturing costs and tariffs.

5. Notable Q&A Insights

• Regulatory Delays: Management acknowledged that regulatory issues contributed to the decline in retina sales but expressed confidence in resolving these challenges moving forward.
• Backlog Impact: An $800,000 backlog in retina orders is expected to positively impact Q2 revenue.
• Focus on Probe Utilization: While system sales were flat, the emphasis remains on increasing probe utilization, particularly among moderate glaucoma patients.
• Gross Margin Expectations: Future gross margins are projected to normalize in the high 30s to low 40s, depending on product and region mix.

Overall, IRIDEX's Q1 2026 results reflect a mixed performance with strong growth in the glaucoma segment but challenges in the retina business due to external factors. The company remains optimistic about its strategic initiatives and financial outlook for the year.